Please assess the completion status of the following clinical trial:

Trial Title: Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male of Female aged 18-65 years.~* Healthy volunteers with a negative history of seasonal or perennial nasal symptoms other than occasional common colds. Atopy will not preclude inclusion into the study as long as patients have no nasal symptoms.~* Current non-smokers (ex-smokers for greater than 6 months duration with a total smoking history of less than 5 pack-years will be eligible).~* PNIF \> 100L/min (best effort of 3) and reversibility with OXY 2 squirts in each nostril (20 min reading) \> 20 L/min.~* Ability to give a written informed consent.~* Ability and willingness to comply with the requirements of the protocol.~Exclusion Criteria:~* Recent respiratory tract/sinus infection within the last 2 months.~* Pregnancy, planned pregnancy or lactation.~* Known or suspected hypersensitivity to any of the IMP's.~* Concomitant use of medicines (prescribed, OTC or herbal) like alpha blockers that may interfere with the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Prazosin 1mg challenge to block alpha 1 adrenoreceptors
- 2 (Type: PLACEBO_COMPARATOR): Placebo to Prazosin

Based on this trial design, predict the completion outcome and termination type (if applicable).